CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 961 enrolled
Drug / intervention
Odiparcil +2 moredrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Women of non-childbearing potential
  • ✓Scheduled for total knee replacement surgery
Key exclusion· 6
  • ✕Allergy to X-ray contrast dye
  • ✕Known allergy or reaction to warfarin or coumadin
  • ✕Prior history of VTE or DVT
  • ✕Current anticoagulation therapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00244725
NCT00244725Phase 2Completed
CompareCT.gov

A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

GlaxoSmithKline·interventional·Posted Oct 27, 2005·Updated May 2, 2017

In Brief

A Phase 2 clinical trial evaluating Odiparcil, Warfarin, and 1 other intervention for Deep Vein Thrombosis and 3 related conditions. Completed, enrolled 961 participants across 101 sites in 13 countries.

Detailed Summary

Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDeep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
CountriesAustralia, Brazil, Canada, India, Israel, Latvia, Lithuania, Poland, Russia, South Africa, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 27, 2005
Enrollment StartSep 1, 2005
Primary CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.7 years ago

Interventions

Odiparcildrug

Warfarindrug

Coumadindrug